Description

TG Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and bringing to market innovative therapies for a range of B-cell cancers and autoimmune conditions. Among its pipeline of therapeutic agents are Ublituximab, an experimental glycoengineered monoclonal antibody targeting B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and various forms of relapsing multiple sclerosis. Also featured is Umbralisib, an orally administered inhibitor specifically designed for PI3K-delta and CK1-epsilon, which addresses CLL, marginal zone lymphoma, and follicular lymphoma. The company's portfolio further includes Cosibelimab, a human IgG1 monoclonal antibody designed to attach to programmed death-ligand 1 (PD-L1) and thus prevent its engagement with PD-1 and B7.1 receptors. Another compound, TG-1701, is an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, demonstrating superior selectivity for BTK over ibrutinib in laboratory kinase assays. Rounding out these developments is TG-1801, a bispecific antibody targeting both CD47 and CD19. Additionally, TG Therapeutics holds licenses for several preclinical stage programs focusing on BET, interleukin-1 receptor associated kinase-4, and GITR. It also maintains collaborative agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. Strategic partnerships have been forged with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S.A. Established in 1993, TG Therapeutics, Inc. operates from its headquarters in New York, New York.